文献速递肝病

综述:成人囊性纤维化肝病的流行病学、发病机制与管理

Review article: epidemiology, pathogenesis and management of liver disease in adults with cystic fibrosis.
PubMed 文献 · Aliment Pharmacol Ther · 2022-01-19

本综述通过文献检索总结了囊性纤维化肝病(CFLD)的流行病学、病理、诊断和管理现状,指出CFLD是囊性纤维化(CF)患者仅次于肺病的首要死因,临床显著CFLD发病率随年龄线性增长至成年早期,在CF患者中可达25%,诊断策略缺乏精确性且有效疗法匮乏, newer modulator疗法在CFLD中缺乏数据且肝毒性风险增加,肝移植结局与非CF移植指征相当。

要点

  • 临床显著CFLD发病率随年龄线性增长至成年早期,在CF患者中可达25%。
  • 诊断策略缺乏精确性,患者风险分层需超越Child-Pugh评分。
  • 有效疗法匮乏,新型调节剂疗法在CFLD中缺乏数据且肝毒性风险增加。

核心结论

  • CFLD发病率随年龄增长而增加,因此对成人CF患者日益重要。
  • 有效疗法匮乏,需更好地理解发病机制和疾病检测才能取得进展。

研究设计与样本

  • 综述:通过文献检索识别并总结囊性纤维化肝病的相关报告。

主要发现

  • CFLD是一种异质性疾病,存在多种共存的病理,包括环境和遗传因素。
  • 临床显著CFLD的发病率持续以线性速率增长至成年早期,在CF患者中描述高达25%。
  • 诊断策略缺乏精确性,患者风险分层需要超越Childs-Pugh评分。
  • 有效疗法匮乏,目前新型调节剂疗法在CFLD中缺乏数据且携带增加的肝毒性风险。
  • 肝移植的结局与非CF移植指征相当。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cystic fibrosis-related liver disease (CFLD) is the leading cause of death in cystic fibrosis (CF), after pulmonary disease. To improve identification and management of this condition requires an understanding of the underlying disease mechanism. AIMS: This review summarises the current understanding of CFLD epidemiology, pathology, diagnosis and management. METHODS: Relevant reports on cystic fibrosis liver disease were identified using a literature search and summarised. RESULTS: CFLD is a heterogeneous condition with several different co-existent pathologies, including environmental and genetic factors. Incidence of clinically significant CFLD continues at a linear rate into early adulthood and has been described in up to 25% of CF patients. Diagnosis strategies lack precision and patient risk stratification needs to look beyond Childs-Pugh scoring. Efficacious therapies are lacking and, at present, newer modulator therapies lack data in CFLD and carry an increased risk of hepatotoxicity. Outcomes of liver transplant are comparable to non-CF transplant indications. CONCLUSIONS: The incidence of CFLD increases with age and hence is increasingly important to adult patients with CF. Effective therapies are lacking. For progress to be made a better understanding of pathogenesis and disease detection are required.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Scott J, Jones AM, Piper Hanley K, et al. Review article: epidemiology, pathogenesis and management of liver disease in adults with cystic fibrosis. Aliment Pharmacol Ther. 2022. PMID: 35048397. doi:10.1111/apt.16749

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。